



Ondansetron

Adjudication Guideline

Rule Category: Pharmaceutical	Ref: No: 2024-PH-41	Version Control: Version No.V1.0	Effective Date: 16/06/2025	Revision Date: 13/05/2025
Approved by: Daman	Responsible: Pharmaceutical Standards& Governance	Related Adjudication Guidelines: N/A		

Table of Contents

1. Abstract	3
1.1 For Members.....	3
1.2 For Medical Professionals.....	3
2. Scope	3
3. Adjudication policy.....	4
3.1 Eligibility / Coverage Criteria.....	5
3.2 Requirements for Coverage.....	5
3.3 Non-coverage.....	5
4. Denial Codes.....	6
5. Appendices	6
5.1 References	6
5.2 Revision History	7

1. Abstract

1.1 For Members

Ondansetron is indicated for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. It is particularly useful for patients who are at risk of severe nausea or vomiting following these treatments. This medication must be taken under medical supervision.

1.2 For Medical Professionals

Ondansetron is primarily indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgical procedures.

2. Scope

The scope of this adjudication rule highlights the medical indications and coverage requirements of Ondansetron drug for all health insurance plans administered by Daman as per policy terms and conditions.

Indications:

Ondansetron is a selective 5-HT3 receptor antagonist used primarily to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It can be administered orally or intravenously.

Mechanism of Action:

Receptor Blocking:

Ondansetron selectively inhibits the 5-HT3 receptors, found in the gastrointestinal tract and the brain's chemoreceptor trigger zone (CTZ).

Peripheral Effects:


By blocking 5-HT3 receptors in the gut, ondansetron reduces serotonin-induced nausea and vomiting.

Central Effects:

In the CTZ, the ondansetron prevents nausea and vomiting triggered by stimuli like chemotherapy and radiation.

Tissue Selectivity:

With a high affinity for 5-HT3 receptors, Ondansetron effectively manages nausea and vomiting while minimizing side effects compared to other antiemetics.



https://www.researchgate.net/figure/Figure-No-1-Ondansetron-HCl-mechanism-of-action-present-the-blocking-of-5-HT-by-fig1_370411689

3. Adjudication policy

3.1 Eligibility / Coverage Criteria

Ondansetron is intended for use under the guidance of a healthcare provider.

Ondansetron is recommended for adult and paediatric patients at risk of nausea and vomiting due to chemotherapy, radiotherapy and following gastrointestinal surgery

Initial Approval Criteria:

- Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV):
 - The patient must have a cancer diagnosis requiring chemotherapy.
 - The chemotherapy regimen should have moderate to high emetogenic potential.
- Prevention of Postoperative Nausea and Vomiting (PONV):
 - The patient is scheduled for surgery with a recognized risk of postoperative nausea and vomiting.
- Prevention of Radiotherapy-Induced Nausea and Vomiting (RINV):
 - The patient is undergoing radiotherapy with a moderate to high risk of nausea and vomiting.
- Management of Gastroenteritis/Colitis:
 - The patient presents with nausea and vomiting due to gastroenteritis or colitis.
- Treatment of Hyperemesis Gravidarum:
 - The patient is between 4 to 20 weeks pregnant and experiencing moderate to severe hyperemesis.

Continuation therapy:

- Members are responding positively to therapy as evidenced by reduced incidence of nausea and vomiting.
- For chemotherapy: Continued use is supported by ongoing moderate to high emetogenic chemotherapy.
- For surgery: Continued use may be considered if patient is at risk of PONV in future surgeries

3.2 Requirements for Coverage

- Kindly code the ICD-10 and the CPT codes to the highest level of specificity

Red flags:

- Ondansetron is not covered for conditions outside of its approved indications (e.g., general nausea unrelated to treatment, vomiting)
- Not covered for patients without a documented risk of moderate to severe nausea and vomiting.

3.3 Non-coverage

- Not covered for visitor plan

4. Denial Codes

- Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

Code	Code Description
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
CODE-010	Activity/diagnosis inconsistent with clinician specialty
NCOV-001	Service(s) is (are) not covered
AUTH-001	Prior-Approval is required and was not obtained
MNEC-005	Service/supply may be appropriate, but too frequent

5. Appendices

5.1 References

[ZOFTRAN \(ondansetron hydrochloride\) Label](#)
[Ondansetron 4 mg film-coated tablets - Summary of Product Characteristics \(SmPC\) - \(emc\)](#)
[National Comprehensive Cancer Network \(NCCN\) Guidelines for Antiemesis, Version 1.2021.](#)
<https://doi.org/10.1213/01.ane.0000295230.55439.f4>
[Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment - UpToDate](#)
<https://www.rcoq.org.uk/media/y3fen1x1/gtg69-hyperemesis.pdf>
<https://www.somanz.org/content/uploads/2020/07/NVP-GUIDELINE-1.2.20-1.pdf>
<https://www.nnuh.nhs.uk/publication/download/hyperemesis-gravidarum-q6-v5/>
<https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17739>

5.2 Revision History

Date	Change(s)
13/05/2025	Release of V1.0

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by The National Insurance Company – Daman (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.